Correlogic Systems and JEOL signed a research and development agreement focused on further enhancing the performance of mass spectrometry in a clinical setting. Correlogic and JEOL have collaborated for more than a year under an informal agreement and have made great strides in the continuing validation of various mass spectrometer-based assays, according to the companies.

“Over the past year, we have had a very close and productive research collaboration with JEOL,” said Peter J. Levine, president and CEO of Correlogic Systems. “This agreement formalizes our link.”

Previous articlePhenomenex to Distribute Beckman Coulter’s IgY Proteome Enrichment Chemistry
Next articleBiomatrica and Qiagen Enter Into Marketing Agreement for Shipment and Storage Products